You are here

Article Text

Article menu

Download PDFPDF

PostScript
Letter
Authors' response
Free
  1. Nicole M Probst-Hensch1,2,
  2. Ivan Curjuric1,2,
  3. Pierre-Olivier Bridevaux3,
  4. Nino Künzli1,2,
  5. Christian Schindler1,2,
  6. Thierry Rochat3
  1. 1Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
  2. 2University of Basel, Basel, Switzerland
  3. 3Division of Pulmonary Medicine, University Hospitals of Geneva, Geneva, Switzerland
  1. Correspondence to Professor Dr Nicole M Probst-Hensch, Unit of Chronic Disease Epidemiology, Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Socinstrasse 57, P O Box, 4002 Basel, Switzerland; nicole.probst{at}unibas.ch

https://doi.org/10.1136/thx.2010.148213

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We appreciate the issues raised by Dr Hoesein regarding our paper1 and respond as follows.

    First, the NELSON study is a randomised screening trial for lung cancer and therefore targets subjects at high risk. The focus of our paper is different. We evaluated the prognostic meaning of a change in prebronchodilation spirometry—a common outcome in environmental epidemiology—in terms of respiratory health, not specifically bound to chronic obstructive pulmonary disease (COPD). We showed that this outcome has value in epidemiological research, but that understanding of the early stages of airflow obstruction, where non-persistence …

    View Full Text

    Linked Articles